About this item:

421 Views | 0 Downloads

Author Notes:

Correspondence: Joseph F. Cubells, Departments of Human Genetics and Psychiatry and Behavioral Sciences, Emory University School of Medicine, 615 Michael Street, Suite 301, Atlanta, GA 30322, USA; Email: jcubell@emory.edu

Disclosures: No potential conflict of interest relevant to this article was reported.

Subjects:

A Head-to-Head Comparison of Risperidone and Divalproex for Treatment of Pediatric Bipolar Disorder

Tools:

Journal Title:

Current Psychiatry Reports

Volume:

Volume 13, Number 2

Publisher:

, Pages 82-83

Type of Work:

Article | Post-print: After Peer Review

Abstract:

There are distressingly few well-controlled clinical trials of psychopharmacologic interventions for childhood psychiatric disorders. Pediatric bipolar disorder (PBD), while the subject of some nosologic controversy, is in its “pure” form a devastating relapsing/remitting disorder that can be very difficult to treat. This National Institutes of Health–supported trial (medication and placebo capsules supplied without cost by the respective manufacturers of risperidone and divalproex) is a welcome addition to the literature, as it compares two of the most commonly recommended medications for mania in PBD, neither of which has a substantial evidence base supporting its use for that indication.

Copyright information:

© Springer Science+Business Media, LLC 2011

Export to EndNote